ArticleThe Journal of biological chemistry2026
Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations in DNA methylation represent one of the earliest molecular events in bladder tumorigenesis and are strongly associated with treatment efficacy and prognosis. Herein, we investigated DNA methylation landscape of MIR141 promoter and elucidated its clinical relevance in bladder cancer (BlCa) patients. miRNA-seq was performed to analyze miRNA profile in bladder tumors. Expression analysis of miR-141-3p and methylation profiling of MIR141 promoter were performed in 15 patient-derived xenografts (PDXs) mouse models, and in our screening patients' cohort (n = 133). TCGA-BLCA (n = 412) was used as independent validation cohort. Survival analysis was performed employing tumor relapse/progression as clinical endpoints in non-muscle-invasive BlCa (NMIBC; TaT1), and mortality in muscle-invasive BlCa (MIBC; T2-T4) patients. Internal validation was conducted through bootstrap analysis, and the clinical benefit of the findings was evaluated using decision curve analysis. miRNA-seq highlighted miR-141-3p as one of the most significantly downregulated miRNAs in muscle-invasive and high-grade tumors, while PDXs, TCGA-BLCA and screening cohort revealed its robust epigenetic regulation through MIR141 core promoter methylation. Consistent with miR-141-3p loss, hypermethylation of MIR141 core promoter was associated with advanced stage and high-grade tumors, reduced survival in PDXs, and significantly higher risk of TaT1 patients for short-term progression to muscle-invasive disease. Multivariate models highlighted MIR141 promoter hypermethylation as independent predictor for NMIBC short-term progression, displaying superior clinical benefit in patients' prognostication. Overall, MIR141 core promoter methylation results in miR-141-3p loss in bladder tumors and correlates with patients' poor treatment outcome, offering improved risk-stratification and addressing prognostic heterogeneity beyond traditional markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.